Taken together, all the 10 patients (100%) with clinical diagnosis of TSC-LAM were found to carry TSC1/2 mutations while only 36 of the 51 (70.6%) patients with clinical diagnosis of S-LAM were found to carry TSC1/2 mutations, with a statistically significant difference between the positive detection rates in these two subgroups (P<0. Here, TSC1 is linked to lymphangioleiomyomatosis.